Although ATRA is capable of inducing APL cells into a differentiated granulocytic phenotype, most evidence suggest that target genes, including differentiation-inducing gene TGM2 and canonical target gene RARβ, remain aberrantly hypermethylated upon ATRA treatment14,45. The gene discussed is TGM2; the disease is acute promyelocytic leukemia.